IOS-1002

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameIOS-1002
Drug Alias Nameios-H2
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionLeukocyte immunoglobulin-like receptor B1 inhibitors
TargetsLeukocyte immunoglobulin-like receptor B1
Therapy Area/IndicationsSolid tumoursHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaSwitzerland
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmunOs Therapeutics AG
China Registration ClassN/A

Develop Information

Active CompaniesImmunOs Therapeutics AG
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A